Pharsight

Mayne Pharma patents expiration

1. Annovera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850251 MAYNE PHARMA System for providing birth control
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg of ethinyl estradiol for up to 1thirteen 21/7-day (in/out) cycles

Dosage: RING;VAGINAL

More Information on Dosage

ANNOVERA family patents

Family Patents

2. Bijuva patents expiration

BIJUVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11865179 MAYNE PHARMA Progesterone formulations having a desirable PK profile
Nov, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793819 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US11529360 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's drug patent expiration?
More Information on Dosage

BIJUVA family patents

Family Patents

3. Doryx patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161 MAYNE PHARMA Modified release coated drug preparation
Dec, 2022

(1 year, 3 months ago)

US8715724 MAYNE PHARMA Tabletting process
Feb, 2028

(3 years from now)

US9511031 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(10 years from now)

US9295652 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(10 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline
Dec, 2034

(10 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX before it's drug patent expiration?
More Information on Dosage

DORYX family patents

Family Patents

4. Fabior patents expiration

FABIOR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688071 MAYNE PHARMA Topical foam composition
Feb, 2030

(5 years from now)

US8808716 MAYNE PHARMA Topical foam composition
Feb, 2030

(5 years from now)

US10568859 MAYNE PHARMA Topical foam composition
Feb, 2030

(5 years from now)

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

FABIOR family patents

Family Patents

5. Lexette patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020407 MAYNE PHARMA Corticosteroid containing foam compositions and method of manufacture thereof
Nov, 2036

(12 years from now)

US10857159 MAYNE PHARMA Halobetasol foam composition and method of use thereof
Nov, 2036

(12 years from now)

US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof
May, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of LEXETTE before it's drug patent expiration?
More Information on Dosage

LEXETTE family patents

Family Patents

6. Nextstellis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(11 months from now)

US11793760 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 2025-04-15

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

More Information on Dosage

NEXTSTELLIS family patents

Family Patents

7. Sorilux patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629128 MAYNE PHARMA Vitamin formulation
May, 2026

(2 years from now)

US8263580 MAYNE PHARMA Vitamin formulation
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Nov 5, 2022

Drugs and Companies using CALCIPOTRIENE ingredient

Market Authorisation Date: 06 October, 2010

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; Use of calcipotriene...

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

SORILUX family patents

Family Patents